André Abrahão
medical directorMale0.0Global Dominance: 0.00%
André Abrahão is the Medical Director of Gilead Sciences Brazil, where he plays a crucial role in the development and introduction of innovative treatments for HIV, including lenacapavir, an injectable medication approved by Anvisa for its potential to prevent HIV infections and treat patients with limited therapeutic options.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
André Abrahão is the Medical Director of Gilead Sciences Brazil and emphasizes the long-term innovation of lenacapavir in expanding prevention options.
Anvisa aprova lenacapavir, 1ª injeção semestral revolucionária que previne a infecção em quase 100%O Globo·
Brazil· 2026-01-12
Brazil· 2026-01-12
André Abrahão is the Medical Director of Gilead Sciences Brazil and emphasizes the long-term innovation of lenacapavir in expanding prevention options.
Anvisa aprova lenacapavir, 1ª injeção semestral revolucionária que previne a infecção em quase 100%O Globo·Brazil· 2026-01-12
Brazil· 2026-01-12